{"id":"sulfadoxine-pyrimethamine-and-chlorproguanil-dapsone","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, vomiting, diarrhea)"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hemolytic anemia (particularly in G6PD-deficient individuals)"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3137690","moleculeType":"Unknown","molecularWeight":"559.05"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Sulfadoxine-pyrimethamine (SP) and chlorproguanil-dapsone (CD) are both antifolate combinations that target sequential steps in the parasite's folate metabolism pathway. Sulfadoxine inhibits dihydropteroate synthase while pyrimethamine inhibits dihydrofolate reductase; similarly, chlorproguanil inhibits dihydrofolate reductase and dapsone inhibits dihydropteroate synthase. This dual mechanism reduces the likelihood of resistance development compared to monotherapy.","oneSentence":"This combination of two antimalarial drugs works by inhibiting folate synthesis in Plasmodium parasites, preventing DNA replication and parasite growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:42.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria treatment and prevention"},{"name":"Plasmodium falciparum malaria in areas with drug resistance"}]},"trialDetails":[{"nctId":"NCT00361114","phase":"PHASE3","title":"IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.","status":"TERMINATED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2006-07","conditions":"Malaria","enrollment":112},{"nctId":"NCT00158574","phase":"PHASE2, PHASE3","title":"Kilimanjaro IPTi Drug Options Trial","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-01","conditions":"Malaria","enrollment":2419},{"nctId":"NCT00158561","phase":"PHASE3","title":"Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-02","conditions":"Malaria, Vivax Malaria","enrollment":750},{"nctId":"NCT00111163","phase":"NA","title":"Intermittent Preventive Treatment With Antimalarials in Kenyan Infants","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"Malaria, Anemia","enrollment":1516},{"nctId":"NCT00164710","phase":"PHASE4","title":"Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-04","conditions":"Malaria, Falciparum","enrollment":365},{"nctId":"NCT00461578","phase":"NA","title":"Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-04","conditions":"Malaria","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"sulfadoxine-pyrimethamine and chlorproguanil-dapsone","genericName":"sulfadoxine-pyrimethamine and chlorproguanil-dapsone","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of two antimalarial drugs works by inhibiting folate synthesis in Plasmodium parasites, preventing DNA replication and parasite growth. Used for Malaria treatment and prevention, Plasmodium falciparum malaria in areas with drug resistance.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}